A multi-institutional group has identified a “signature” of metabolic molecules associated with exercise-induced physiologic deficits that, when released into the bloodstream, signal heightened heart failure risk. Eric Gamazon, PhD, and Ravi Shah, MD, Department of Medicine faculty, are part of the research group.
The award recognizes individuals who demonstrate “outstanding promise” in physiological sciences research.
Ela Knapik, MD, (Genetic Medicine and Clinical Pharmacology) is among six Vanderbilt faculty members who have been elected honorary fellows of the American Association for the Advancement of Science (AAAS) for their contributions to advancing scientific knowledge and its applications.
Yash Pershad, an MD/PhD student in the lab of Alexander Bick, MD, PhD, is the first author of the paper, published this month in JAMA Cardiology.
Co-corresponding authors of the study are Xue Zhong, PhD, and Nancy Cox, PhD, Department of Medicine faculty members in the Division of Genetic Medicine and Clinical Pharmacology.
According to a study published last week in JAMA Oncology by Alex Bick, MD, PhD (Genetic Medicine) and colleagues, patients who have been diagnosed with clonal hematopoiesis of indeterminate potential (CHIP) are at an increased risk for heart disease following cancer treatment.
This year, several Department of Medicine faculty were appointed to new positions that will help advance the department and medical center missions.
Annet Kirabo, DVM, MSc, PhD, associate professor of Medicine (Genetic Medicine and Clinical Pharmacology), has been ranked as a 2025 Top Scholar by the global academic analytics platform ScholarGPS.
VUMC recently held a Directorship Celebration to honor 23 leaders, including seven in the Department of Medicine, from across the enterprise in clinical care, research, education and administration.
According to research recently published in JAMA Dermatology by Elizabeth Phillips, MD, and colleagues, a newly identified genetic marker, HLA-A*34:02, may significantly improve the ability to predict life-threatening reactions to the gout medication allopurinol in U.S. patients.
